Sort
82,697 grants matching “vaccine development”
Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C
$1,060,516T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2016 · DK
CAP-IT Center for LNP RNA Immunoprevention
$1,060,438Steven Monroe Lipkin · Weill Medical Coll Of Cornell Univ · U54 · FY2024 · CA
Immune signatures of vaccine responses in vulnerable populations
$1,060,433Ruth R Montgomery · Yale University · U19 · FY2024 · AI
Functional and genetic constraints on influenza virus replication and fidelity
$1,060,424Adam Lauring · University Of Michigan At Ann Arbor · R01 · FY2025 · AI
Developmental Core (Core B)
$1,060,339Gwendolyn B. Scott · University Of Miami School Of Medicine · P30 · FY2020 · AI
Center for Computational Mass-Spectrometry
$1,060,209Pavel A Pevzner · University Of California, San Diego · P41 · FY2013 · GM
GLOBAL HIV VACCINE ENTERPRISE
$1,060,037Alan Bernstein · Global Hiv Vaccine Enterprise · N01 · FY2010 · AI
DNA 3.0: Development of a novel, efficient and cost-effective enzymatic process for synthesis of DNA oligonucleotides
$1,059,968Helge Zieler · Primrose Bio, Inc. · R44 · FY2022 · HG
Adjuvants and Toll-like Receptors in Vaccine Development
$1,059,777Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · P01 · FY2008 · AI
Cape Town Clinical Trials Unit (CT-CTU) for HIV/AIDS Prevention & Treatment
$1,059,759Robin Wood · University Of Cape Town · U01 · FY2010 · AI
A Rapid Portable HIV Detection and Monitoring System for Low Resource Settings
$1,059,746Robert Juncosa · Thermal Gradient, Inc. · R44 · FY2015 · AI
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV
$1,059,338Kathleen Schmeler · University Of Tx Md Anderson Can Ctr · U54 · FY2024 · CA
SBIR Phase II: Megathura Crenulata Post Larval Culture - Bottleneck for a Valuable Medical Resource
$1,059,224Frank R Oakes · Stellar Biotechnologies, Inc. · · FY2009 · TIP
Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes
$1,059,206Frederick Porter · Duke University · U19 · FY2019 · AI
Clinical and translational evaluation of vector saliva based vaccination strategies for Zika and other important or emerging vector-borne diseases
$1,058,474Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Establish a Public Private Partnership for COVID19 Research
$1,058,410David N. Wholley · Foundation For The Nih · OT2 · FY2023 · OD
NJMS Clinical Trials Unit: Targeting Pediatric, Adolescent, and Material HIV Infe
$1,058,279James Oleske · Univ Of Med/Dent Of Nj-Nj Medical School · U01 · FY2007 · AI
Molecular Approaches To Antiviral and Vaccine Development For Hepatitis C
$1,058,228T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2017 · DK
Laboratory And Preclinical Studies Of Flaviviruses
$1,057,919Stephen Whitehead · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Antidotes to Anthrax Lethal Factor Intoxication
$1,057,909Alan Thomas Johnson · Panthera Biopharma, Llc · U01 · FY2010 · AI
HERPESVIRUSES AS VACCINE VECTORS FOR AIDS
$1,057,488Harvard University (Medical School) · P01 · FY2001 · AI
Production Development
$1,057,404Niranjan Y Sardesai · Wistar Institute · U19 · FY2017 · AI
Development of a Preclinical Assay to Predict Efficacy of Ricin Toxin Subunit Vaccines
$1,057,355Nicholas J Mantis · Wadsworth Center · R01 · FY2017 · AI
AIDS International Training and Research Program (AITRP)
$1,057,030Arthur L. Reingold · University Of California Berkeley · D43 · FY2007 · TW
Development of humanized models using human induced pluripotent stem cells
$1,056,953John K. Critser · University Of Missouri-Columbia · RC2 · FY2009 · HL